Premium
Physiological effects of titrated oxygen via nasal high‐flow cannulae in COPD exacerbations: A randomized controlled cross‐over trial
Author(s) -
Pilcher Janine,
Eastlake Leonie,
Richards Michael,
Power Sharon,
Cripps Terrianne,
Bibby Susan,
Braithwaite Irene,
Weatherall Mark,
Beasley Richard
Publication year - 2017
Publication title -
respirology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.857
H-Index - 85
eISSN - 1440-1843
pISSN - 1323-7799
DOI - 10.1111/resp.13050
Subject(s) - medicine , copd , crossover study , anesthesia , exacerbation , oxygen saturation , randomized controlled trial , pulse oximetry , respiratory rate , respiratory system , oxygen therapy , oxygen , surgery , heart rate , placebo , blood pressure , chemistry , alternative medicine , organic chemistry , pathology
Background and objective Increased arterial carbon dioxide tension ( PaCO 2 ) is an important complication of acute exacerbations of COPD . The effects of nasal high‐flow cannulae ( NHF ) on PaCO 2 in patients with COPD exacerbations, and whether this therapy should be used in this clinical situation, are less certain. We aimed to investigate the effect of NHF on PaCO 2 in patients admitted to hospital with a COPD exacerbation. Methods We performed a single‐centre randomized controlled cross‐over trial in 24 hospital inpatients with acute exacerbations of COPD receiving oxygen via standard nasal prongs ( SNPs ). Patients received both supplemental oxygen via NHF (35 L/min) and SNP for 30 min each, with oxygen titrated to maintain the patient's baseline oxygen saturation, measured by pulse oximetry ( SpO 2 ). Interventions were administered in random order with a minimum 15‐min washout between interventions. The primary outcome was difference in transcutaneous carbon dioxide tension ( PtCO 2 ) at 30 min adjusted for time zero. Results The difference in PtCO 2 adjusted for time zero was lower after 30 min for NHF compared with SNP (−1.4 mm Hg (95% CI : −2.2 to −0.6), P = 0.001). There was no difference in SpO 2 at 30 min (−0.02% (95% CI : −0.8 to 0.7), P = 0.96). The reduction in respiratory rate for NHF at 30 min was not statistically significant (−2.0 breaths/min (95% CI : −4.5 to 0.4), P = 0.099). Conclusion Short‐term use of NHF results in a small reduction in PtCO 2 compared with SNP in patients with acute exacerbations of COPD , but whether this is clinically significant is uncertain.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom